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Effect of Chlorhexidine/Silver Sulfadiazine-Impregnated
Central Venous Catheters in an Intensive Care Unit with
a Low Blood Stream Infection Rate after Implementation
of an Educational Program: A Before–After Trial*
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ABSTRACT
Background: Current guidelines recommend using antiseptic- or antibiotic-impregnated cen-
tral venous catheters (CVCs) if, following a comprehensive strategy to prevent catheter-re-
lated blood stream infection (CR-BSI), infection rates remain above institutional goals based
on benchmark values. The purpose of this study was to determine if chlorhexidine/silver sul-
fadiazine-impregnated CVCs could decrease the CR-BSI rate in an intensive care unit (ICU)
with a low baseline infection rate.
Methods: Pre-intervention and post-intervention observational study in a 24-bed surgi-
cal/trauma/burn ICU from October, 2002 to August, 2005. All patients requiring CVC place-
ment after March, 2004 had a chlorhexidine/silver sulfadiazine-impregnated catheter inserted
(post-intervention period).
Results: Twenty-three CR-BSIs occurred in 6,960 catheter days (3.3 per 1,000 catheter days)
during the 17-month control period. After introduction of chlorhexidine/silver sulfadiazine-
impregnated catheters, 16 CR-BSIs occurred in 7,732 catheter days (2.1 per 1,000 catheter days;
p  0.16). The average length of time required for an infection to become established after
catheterization was similar in the two groups (8.4 vs. 8.6 days; p  0.85). Chlorhexidine/silver
sulfadiazine-impregnated catheters did not result in a statistically significant change in the
microbiological profile of CR-BSIs, nor did they increase the incidence of resistant organ-
isms.
Conclusions: Although chlorhexidine/silver sulfadiazine-impregnated catheters are useful
in specific patient populations, they did not result in a statistically significant decrease in the
CR-BSI rate in this study, beyond what was achieved with education alone.
*Some of the material contained herein was presented orally (no written abstract) at the 35th Critical Care Congress,
Society of Critical Care Medicine, San Francisco, January 23, 2006.
Departments of 1Surgery, 4Genetics, 5Internal Medicine, and 6Anesthesiology, Washington University School of
Medicine, St. Louis, Missouri.
Departments of 2Hospital Epidemiology and Infection Control and 3Nursing Barnes-Jewish Hospital, St. Louis,
Missouri.
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THE U.S. CENTERS FOR DISEASE CONTROL ANDPREVENTION (CDC) estimate that 250,000
catheter-related blood stream infections (CR-
BSIs) occur annually in the United States [1],
although the incidence of this complication dif-
fers among countries [2]. The mortality rate of
CR-BSI is controversial, with estimates ranging
from 0 to 35% [3–8]. Although the attributable
mortality rate of a CR-BSI is unclear, these in-
fections place a substantial burden on the
health care system, because they increase
length of stay [4,6–8] and have been estimated
to cost as much as $56,167 (in 1998 dollars) in
an intensive care unit (ICU) patient [9].
Exposure to central venous catheters (CVCs)
is common in ICU patients, with utilization
rates ranging from 0.36 CVC days/total patient
days in coronary care units to 0.83 CVC
days/total patient days in cardiothoracic ICUs.
Surgical and medical ICUs have rates of 0.63
and 0.52, respectively [10]. Despite the high rate
of CVC utilization in ICUs, multiple studies
have shown that most CR-BSIs are preventable,
if not all. One successful strategy is the imple-
mentation of an educational program aimed at
physicians, nurses, or the entire multidiscipli-
nary ICU team [11–16]. These programs typi-
cally stress adherence to best-practice behav-
iors known to prevent CR-BSIs, including the
use of full barrier precautions [17], 2%
chlorhexidine skin preparation at the insertion
site [18], appropriate hand hygiene [19,20], and
specifying the anatomic site of CVC placement
(preferably the subclavian vein, then internal
jugular, lastly femoral vein) [21–23]. Whereas
the decrease in CR-BSIs varies depending on
which intervention is being studied, a recent
study by Berenholtz et al. demonstrated almost
complete elimination of CR-BSIs from a surgi-
cal ICU after initiation of a comprehensive pre-
vention program [24].
Another tool to prevent CR-BSIs is the use
of antiseptic- or antimicrobial-impregnated
catheters. To date, there have been 19 ran-
domized trials, three meta-analyses, and two
cost-benefit analyses of the efficacy of either
chlorhexidine/silver sulfadiazine- or minocy-
cline/rifampin-impregnated catheters [25]. The
majority of these studies demonstrated signif-
icant decreases in CR-BSI rates without the de-
velopment of resistant organisms, regardless of
which catheter was used [26,27]. Of note, place-
ment of antiseptic-impregnated catheters is ef-
fective in decreasing CR-BSI if evidence-based
practices are adhered to, but infection rates are
still higher than desired [28]. The accumulated
weight of these studies has resulted in recom-
mendations from the CDC [1], the Agency for
Healthcare Research and Quality [29], and
thought leaders in the field [30,31] to use anti-
septic- or antimicrobial-impregnated catheters
in select patient populations, although the effi-
cacy of these devices has not been accepted uni-
versally [32].
Because antiseptic- or antimicrobial-impreg-
nated catheters are more expensive than stan-
dard CVCs, but the attributable cost of an in-
fection is much greater than the cost of a
catheter, there has been substantial interest in
determining at-risk populations that would
benefit most from the use of these catheters.
The CDC recommends that an antiseptic- or an-
timicrobial-impregnated CVC be placed “in
adults whose catheter is expected to remain in
place 5 days if, after implementing a com-
prehensive strategy to reduce rates of CR-BSI,
the CR-BSI rate remains above the goal set by
the individual institution based on benchmark
rates and local factors” [1]. “Comprehensive
strategy” is defined as an educational program
directed toward those who insert and maintain
CVCs, as well as usage of both maximum bar-
rier precautions and 2% chlorhexidine for skin
preparation for CVC insertion.
Few data exist currently on the efficacy of an-
tiseptic- or antimicrobial-impregnated catheters
in ICUs that have instituted the comprehensive
strategy outlined by the CDC. The purpose of
this study was to address that specific question—
what is the utility of antiseptic- or antibiotic-
impregnated catheters (specifically chlorhexi-
dine/silver sulfadiazine-impregnated catheters)
in an ICU with low infection rates after a suc-
cessful educational program to prevent CR-BSI?
Previously, we instituted educational and be-
havioral interventions designed to prevent CR-
BSI [11,12], resulting in infection rates that were
one-third the United States national average, as
determined by the National Nosocomial Infec-
tions Surveillance (NNIS) system at the time of
publication. To determine if there was addi-
tional efficacy in using chlorhexidine/silver
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sulfadiazine-impregnated catheters despite our
low CR-BSI rates, we studied the effect of in-
serting these catheters in all patients in our sur-
gical ICU over an 18-month time span.
PATIENTS AND METHODS
Study location and patient population
Barnes-Jewish Hospital is a 1,344-bed ter-
tiary-care, university-affiliated teaching hospi-
tal. All patients admitted to the surgical ICU
between October 1, 2002, and August 31, 2005,
were enrolled in the study. The surgical ICU
admits all critically ill non-cardiothoracic and
non-neurosurgical surgical and trauma pa-
tients. Between October, 2002 and March, 2003,
the surgical ICU had 18 beds. After a three-
month transition, when the number of beds
was variable, the surgical ICU expanded to 24
beds in May, 2003. This is reflected in an in-
crease in yearly admissions from 1,499 in 2003
to 1,636 in 2004. The average length of stay was
constant throughout the study at 4.3 days, as
were nursing staff ratios. Throughout the
study, all patients admitted to the surgical ICU
were followed prospectively by an infection
control team and surveyed for blood stream in-
fections. Data for this study were collected af-
ter completion of our published educational
and behavioral interventions to prevent CR-BSI
in the surgical ICU [11,12].
Demographic data (age, CVC duration,
Acute Physiology and Chronic Health Evalua-
tion [APACHE] II score, ICU and hospital
length of stay, CVC insertion site) were re-
trieved from the Project IMPACT database
(Cerner, Inc., Kansas City, MO). Demographic
data from a patient were recorded only once,
regardless of how many CVCs were inserted.
Prior to March 2004, this database was incom-
plete for most months. Thus, the demographic
data presented in the pre-intervention group
that did not have routine placement of
chlorhexidine/silver sulfadiazine-impreg-
nated catheters consist of data from only three
non-contiguous months. To determine whether
the patient population in the surgical ICU
changed over the course of the study, demo-
graphic data from patients admitted before
March, 2004 (pre-intervention) were compared
and found to be similar to both the post-inter-
vention group from March, 2004–August, 2005
(where data were collected on all patients for
18 months) and all admissions to the surgical
ICU for a six-month period earlier in 2002 (data
not shown).
Each infection was classified as primary or
secondary according to the CDC definitions
used in previous publications on CR-BSI from
our institution. A CR-BSI was defined as (1) a
pathogen isolated from blood culture not re-
lated to infection at another site; or (2) fever
38.5°C, chills, or hypotension and either of
the following: (a) A common skin contaminant
isolated from two blood cultures drawn on sep-
arate occasions unrelated to infection at an-
other site; or (b) a common skin contaminant
isolated from a blood culture from a patient
with a CVC for which the physician initiated
antimicrobial therapy.
Updates on CR-BSI rates were reported
monthly at the surgical ICU’s quality im-
provement conference and were compared
with both prior rates within the surgical ICU
and the published NNIS rates. The study was
approved by the Washington University
School of Medicine Human Studies Committee,
and informed consent was waived.
Study design
Patients admitted to the surgical ICU prior to
March 2004 (pre-intervention group) had con-
ventional CVCs placed. Although chlorhexi-
dine/silver sulfadiazine-impregnated catheters
have been available commercially for years,
they were not available in the ICU during the
pre-intervention period in accordance with
hospital policy at the time. All patients admit-
ted to the surgical ICU after March, 2004 who
required CVC insertion had chlorhexidine/sil-
ver sulfadiazine-impregnated catheters (Ar-
rowgard Blue Plus; Arrow International, Read-
ing, PA) placed (post-intervention group, with
the intervention defined as the placement of
chlorhexidine/silver sulfadiazine-impregnated
catheters in patients who required a CVC).
These second-generation catheters have both
external coating and internal impregnation.
The fact that all patients received these
448 SCHUERER ET AL.
catheters was based on a decision that any CVC
placed in the surgical ICU was likely to stay in
place for five days, and therefore met the CDC
criteria for placement of antiseptic-impreg-
nated catheters. Of note, mandatory educa-
tional modules on how to prevent CR-BSI con-
tinued on a regular basis throughout the study
for both physicians and nurses in the surgical
ICU.
A pre-hoc decision was made that the pri-
mary endpoint would be CR-BSI rates for CVCs
placed in the surgical ICU, whereas the CR-BSI
rate for all CVCs was a secondary endpoint re-
gardless of whether they were placed inside or
outside the surgical ICU. The rationale behind
this decision was to eliminate the confounding
effect of non-impregnated CVCs placed in the
operating room, emergency department, hos-
pital wards, interventional radiology depart-
ment, or another hospital in the primary analy-
sis. When examining the secondary endpoint
of CR-BSI rates regardless of where a CVC was
placed, a potential confounder was that some
CVCs were placed immediately prior to a pa-
tient’s admission (in the operating room),
whereas some (e.g., Hohn catheters; Bard Ac-
cess Systems, Salt Lake City, UT) were placed
weeks or months earlier. Because there was no
way of knowing how long every one these de-
vices had been in place, catheter days for all
lines were calculated by convention, assuming
they were placed on admission to the surgical
ICU. The calculated CR-BSI rates presented for
all CVCs therefore likely represent overesti-
mates of the true infection rate. The CR-BSI
rates were calculated as infections/1,000
catheter days for the duration of the study.
Each day a patient had a CVC in place was
counted as a catheter day, regardless of the
number of CVCs a patient had at a given time
(i.e., the small minority of patients with multi-
ple catheters in place simultaneously was
counted daily as representing one catheter
day).
All CVCs placed in the surgical ICU through-
out the study were inserted by residents, fel-
lows, two full-time nurse practitioners, or at-
tending physicians. The residents were from
the departments of surgery (post-graduate year
[PGY]-1 and -2), anesthesiology (PGY-1–3), or
emergency medicine (PGY-2) during their sur-
gical ICU rotation. All procedures were super-
vised by surgery, anesthesiology, or pul-
monary/critical care fellows or by the attend-
ing physicians (50% each from the departments
of surgery or anesthesiology). Peripherally in-
serted catheters and arterial catheters were ex-
cluded from study analysis.
On the basis of the results in the pre-inter-
vention group, described below, the study was
powered to determine if antiseptic-impreg-
nated catheters would result in a 60% decrease
in CR-BSI (i.e., similar to that achieved with ed-
ucation alone) [11]. This was done using a base
frequency of 0.00330 (23/6,960), an alpha of
0.05, 80% power, and an expected post-inter-
vention group of 7,000 catheter days. With a
one-tailed test, statistical significance would be
demonstrated if the number of infections de-
creased to 9.
Statistical analysis
Data were analyzed using the statistical soft-
ware program Prism 3.0 (GraphPad Software,
San Diego, CA). Infection rates and contin-
gency tables (i.e., when comparing insertion
site in the pre- and post-intervention groups)
were analyzed using the chi-square test. De-
mographic and microbiology comparisons be-
tween the pre- and post-intervention groups
were performed using the Mann-Whitney U-




There were 4,630 patients admitted to the
surgical ICU during the 35 months of the
study: 2,079 in the 17 months from October,
2002 to February, 2004 (prior to the institution
of chlorhexidine/silver sulfadiazine-impreg-
nated catheters) and 2,551 in the 18 months
from March 2004 to August 2005 (when all pa-
tients receiving a CVC had an antiseptic-im-
pregnated catheter inserted). Throughout the
study, slightly more than one-third of all CVCs
were placed in the surgical ICU, whereas the
remainder were inserted in other locations
(e.g., operating room, emergency department,
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interventional radiology department). Demo-
graphics were similar in the pre-intervention
and post–intervention groups except for a
slightly higher APACHE II score in the post-
intervention group (Table 1). The majority of
CVCs were placed in the internal jugular vein,
but this was attributable predominantly to
placement of CVCs in the operating room
(where insertion was nearly exclusively in the
internal jugular); the majority of CVCs inserted
in the surgical ICU were placed in the subcla-
vian vein (data not shown). Of note, simply
having a CVC in place was a marker of illness
severity throughout the study because patients
who had a CVC had higher mean APACHE II
scores (18.2 vs. 15.6) and longer mean lengths
of stay (6.9  1.1 vs. 4.3  7.2 days) than those
without CVCs.
Catheter-related BSI in CVCs placed 
in surgical ICU
An average of 49 CVCs were placed per
month in the surgical ICU throughout the
study (range 15 to 64). There were 23 CR-BSIs
in 6,960 catheter days of CVCs placed in the
surgical ICU in the pre-intervention group (3.3
per 1,000 catheter days). After the introduction
of chlorhexidine/silver sulfadiazine-impreg-
nated catheters, there were 16 CR-BSIs in 7,732
days (2.1 per 1,000 catheter days; p  0.16).
When examined over six-month increments,
the infection rates were variable throughout the
study (Table 2).
The demographics of the patients who de-
veloped CR-BSI in CVCs placed in the surgical
ICU were similar regardless of whether the in-
fection was of a standard catheter or a chlorhex-
idine/silver sulfadiazine-impregnated catheter
(Table 3). Length of stay and anatomic site of
catheter insertion also were similar. The aver-
age length of time a surgical ICU-placed CVC
was indwelling prior to the development of
CR-BSI was more than eight days, which is sub-
stantially greater than the average length of
time the “typical” CVC remained in place, con-
sidering that fewer than 20% of all CVCs were
indwelling for longer than seven days (com-
pare length of catheterization for all CVCs in
Table 1 with the duration of catheterization in
CVCs that became infected in Table 3). No sta-
tistically significant differences in microbial
isolates were noted in infections of CVCs
placed in the surgical ICU, regardless of
whether the patient had a standard catheter or
a chlorhexidine/silver sulfadiazine-impreg-
nated catheter, with gram-positive organisms
predominating in both groups (Table 4).
Catheter-related BSI in all CVCs
In addition to these infections of CVCs placed
in the surgical ICU, there were six CR-BSIs in
CVCs placed prior to patient arrival in the sur-
TABLE 1. DEMOGRAPHICS OF PATIENTS WITH CENTRAL VENOUS CATHETER
Pre-interventiona Post-interventionb P value
Where catheter placed (%) 0.56
In surgical ICU 34.0 39.0
Outside surgical ICU 66.0 61.0
Age (years) 60.4  0.7 58.9  2.5 0.35
Mean catheter duration (days) 2.8  1.0 3.6  0.7 0.12
7 days (%) 83.0 82.8
7–10 days (%) 12.1 11.9
10 days (%) 4.9 5.3
Mean APACHE II score 17.1  1.2 18.2  0.6 0.04
Mean ICU length of stay (days) 7.0  0.8 6.9  1.1 0.87
Mean hospital length of stay (days) 25.6  2.9 26.6  7.3 0.83
Insertion site (%) 0.85
Subclavian vein 35.5 39.3
Internal jugular vein 57.3 52.6
Femoral vein 7.2 8.1
aBased on sampling of three months on 161 patients.
bN  1,480 patients.
ICU  intensive care unit; APACHE  Acute Physiology and Chronic Health Evaluation.
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gical ICU in both the pre- and post-intervention
groups. Among all CVCs, there were 29 infec-
tions in the pre-intervention group (4.2 per 1,000
catheter days) and 22 infections in the post-in-
tervention group (2.7 per 1,000 catheter days, p 
0.15), including 16 of chlorhexidine/silver sulfa-
diazine-impregnated catheters placed in the sur-
gical ICU and six of standard catheters placed
elsewhere. By comparison, in 2004, the NNIS
rate for surgical ICUs nationwide was 3.4 per
1,000 catheter days. At all times during the
study, the CR-BSI rates were lower than the
NNIS rates published for that year, despite the
fact that NNIS rates have declined steadily over
the past three years [10,33]. Of note, the rate of
secondary blood stream infections did not
change throughout the study, with 28 sec-
ondary BSIs in both the pre-intervention and
post-intervention time periods.
DISCUSSION
This study demonstrates that placing
chlorhexidine/silver sulfadiazine-impregnated
catheters in all surgical ICU patients requiring
CVC insertion failed to result in a statistically
significant decrease in CR-BSI rates below the
already-low rates obtained as the result of a
comprehensive educational program and ad-
herence to best-practice behaviors. Despite ex-
amining a number of infection-related para-
meters and having more than 600 CVCs placed
in each group, chlorhexidine/silver sulfadi-
azine-impregnated catheters had no statisti-
cally significant impact on any endpoint ex-
amined.
There is little question that antiseptic- or an-
tibiotic-impregnated catheters can prevent in-
fection when used in the proper circumstances,
because the preponderance of published liter-
ature on the subject supports their use. As such,
our data do not refute the CDC recommenda-
tion to use these catheters when a CVC is ex-
pected to be in place for five days, CR-BSI rates
are above an institutional goal despite an edu-
cational program, and both maximum barrier
precautions and 2% chlorhexidine skin prepa-
ration are used. What is unclear from the CDC
recommendation is what constitutes an appro-
TABLE 2. CR-BSI RATES AT SIX-MONTH INTERVALS OF CENTRAL VENOUS CATHETERS PLACED IN SURGICAL ICU
Primary Total rate for period:
infections CVC days Infections/1,000 CVC days infections/1,000 CVC days
Pre-intervention
October, 2002–March, 2003 4 2,343 1.7
April, 2003–September, 2003 11 2,470 4.4 3.3
October, 2003–February, 2004a 8 2,147 3.7
Post-intervention
March, 2004–August, 2004 2 2,578 0.8
September, 2004–February, 2005 5 2,402 2.1 2.1
March, 2005–August, 2005 9 2,752 3.3
aFive-month interval.
CR-BSI  catheter-related blood stream infection; CVC  central venous catheter.
TABLE 3. DEMOGRAPHICS OF PATIENTS HAVING CATHETER-RELATED BLOOD STREAM INFECTIONS
FROM CENTRAL VENOUS CATHETERS PLACED IN SURGICAL INTENSIVE CARE UNIT
Pre-intervention Post-intervention P value
Mean age (years) 55.5  17.5 55.2  20.0 0.97
Male (%) 13 (56.0) 9 (56.0) 1.00
Mean catheter time prior 8.4  2.9 8.6  3.2 0.70
to infection (days)
Insertion site (%) 0.14
Subclavian vein 17 (73.9) 8 (50.0)
Internal jugular vein 5 (21.8) 8 (50.0)
Femoral vein 1 ( 4.3) 0 (50.0)
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priate institutional goal. In light of the fact that
published data indicate that CR-BSI can be
eliminated, we made the determination that the
goal infection rate for the surgical ICU at
Barnes-Jewish Hospital should be zero. Thus,
strict implementation of the CDC guidelines
would result in our using antiseptic- or antibi-
otic-impregnated catheters (either chlorhexi-
dine/silver sulfadiazine or minocycline/ri-
fampin) for all patients expected to have a
catheter in place longer than five days. How-
ever, our results do not provide compelling ev-
idence to justify placing chlorhexidine/silver
sulfadiazine-impregnated catheters, although
we cannot determine if minocycline/rifampin-
impregnated catheters would have yielded
similar results, nor can we rule out a true dif-
ference with chlorhexidine/silver sulfadiazine
catheters that this study was not powered to
detect.
The demographics of all patients with CVCs
were strikingly similar throughout the 35
months of the study, as were the characteristics
of the patients whose catheters became infected,
regardless of whether the devices were chlorhex-
idine/silver sulfadiazine-impregnated. One in-
teresting note was the non-significant trend to-
ward more episodes of fungemia after the
institution of chlorhexidine/silver sulfadiazine-
impregnated catheters. Whereas numerous
studies have demonstrated no change in infec-
tion patterns after the introduction of antiseptic-
or antimicrobial-impregnated catheters, combin-
ing the data contained herein with those from
previous studies from our surgical ICU identi-
fied two episodes of fungemia over 56 months
prior to the usage of chlorhexidine/silver sulfa-
diazine-impregnated catheters compared with
four in the subsequent 18 months. Longer-term
follow-up would be needed to determine the
veracity of this finding, which still would not
prove causality.
This study has a number of limitations. The
first is simply our conclusion that there is no
benefit in using chlorhexidine/silver sulfadi-
azine-impregnated catheters in an ICU where
infection rates already are low following an ed-
ucational program and compliance with best-
practice behaviors. Despite there being 800 ad-
ditional catheter days in the post-intervention
group, there were seven fewer infections, a 30%
decrease in the rate of BSI. Our conclusion of
non-significance is based solely on the pre-de-
termined establishment of an alpha of 0.05.
Because our previous educational program de-
creased CR-BSI rates more than 70%, we pow-
ered this study to detect a similar decrease 
in infections, not a 30% decrease. Clearly, if
chlorhexidine/silver sulfadiazine-impregnated
catheters actually decrease CR-BSI rates by
30%, this would be both biologically meaning-
ful and cost-effective, even though it would not
have been identified by the present study. With
our low baseline BSI rate, a power analysis in-
dicates that more than 35,000 catheter days
would have been required in both the pre-in-
tervention and the post-intervention groups to
demonstrate a decrease of 30% in the CR-BSI
TABLE 4. MICROORGANISMS ISOLATED FROM PATIENTS WITH CATHETER-RELATED BLOOD STREAM
INFECTIONS FROM CENTRAL VENOUS CATHETERS PLACED IN SURGICAL INTENSIVE CARE UNIT
Pre-intervention (%) Post-intervention (%)
Gram-positive bacteria 17 (73.9) 8 (50)
Coagulase-negative staphylococci 7 3 
Enterococcus faecalis 7 3 
Enterococcus faecium (vancomycin-resistant) 2 2 
Staphylococcus aureus (methicillin-resistant) 1 0 
Gram-negative bacteria 5 (21.8) 4 (25)
Acinetobacter baumannii 4 1 
Pseudomonas aeruginosa 1 1 
Enterobacter cloacae 0 1 
Serratia marcescens 0 1 
Yeast 1 ( 4.3) 4 (25)
Aspergillus spp. 1 0 
Candida albicans 0 3 
Candida parapsilosis 0 1 
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rate. Such power is not feasible in a single-in-
stitution study. Because the study was designed
to only look for a major decrease in CR-BSI, it
is possible that it fails to recognize the signifi-
cance of a more modest decrease in infection
rates, even if one is truly present. The substan-
tial variability of our infection rates from
month to month (Table 2), although we mini-
mized this variability as much as possible by
comparing aggregate data from 17 months pre-
intervention and 18 months post-intervention,
means that observation over a different time
period might have yielded a different result.
Other limitations exist in the study design.
Compared with a randomized trial, a pre/post
study is susceptible to temporal bias attribut-
able to unrecognized changes in patient popu-
lations or ICU practices. This study also could
have been biased toward the intervention
group, because there was no blinding to the use
of the chlorhexidine/silver sulfadiazine-im-
pregnated catheters. Further, we made the a pri-
ori decision that all CVCs placed in the surgi-
cal ICU had a substantial chance of being in
place for five days to meet the CDC recom-
mendation for antiseptic or antimicrobial
catheter placement. However, the data pre-
sented in Table 1 demonstrate that more than
80% of the CVCs in the surgical ICU were in
place for fewer than seven days. This discrep-
ancy is not as great as it might seem, because
the majority of CVCs were placed outside the
surgical ICU, and these were likely to be in
place for a shorter time than catheters placed in
the surgical ICU because CVCs placed in the
emergency department are considered contam-
inated by convention and are removed within
24–48 h, whereas catheters placed in the oper-
ating room frequently are intended for intra-op-
erative monitoring and are removed shortly af-
ter surgery if no major complications occur. In
contrast, CVCs placed in the surgical ICU gen-
erally are placed because long-term (e.g., par-
enteral nutrition) or reliable access (e.g., vaso-
pressor therapy, determination of intravascular
volume status) is needed, which makes it more
likely that a CVC placed in the surgical ICU will
be present for longer than five days. Nonethe-
less, some unknown percentage of CVCs placed
in the surgical ICU during this study were likely
to have been removed within five days, which
could confound our results. This difference in
duration depending on where a catheter was
placed (e.g., emergency department, surgical
ICU) likely explains why more than 60% of the
CVCs were placed outside the surgical ICU and
yet infections in these non-antibiotic-impreg-
nated catheters made up only a small percent-
age of the overall CR-BSI in both the pre-inter-
vention and the post-intervention group. The
lack of demographic data for 14 of 17 months
in the pre-intervention group also is a limita-
tion. Although the demographic data for three
non-contiguous months were similar to those
for the post-intervention group (and to those
from the six months prior to the start of this
study), we cannot rule out a transient change in
patient population in 2003 that could have af-
fected the results of this study. It is important
to note that whereas some demographic data
are missing for the pre-intervention group, the
infection data were obtained using a different
database and reflect accurately all 4,630 patients
and 14,692 catheter days throughout the dura-
tion of the study.
A final limitation is the catheter used.
Whereas there are substantial data supporting
the benefit of chlorhexidine/silver-sulfadi-
azine-impregnated catheters [34–36], there also
are studies that do not demonstrate a signifi-
cant decrease in CR-BSI with their usage
[37–39]. Because minocycline/rifampin-im-
pregnated catheters have been shown to be su-
perior to first-generation chlorhexidine/silver
sulfadiazine-impregnated catheters [40], it is
possible that different results would have been
obtained had we used minocycline/rifampin-
impregnated catheters.
Despite these limitations, this study has im-
portant implications for ICUs that have been
successful in decreasing CR-BSI rates below
NNIS averages, but have been unable to bring
their rates to zero. In the subset of ICUs that
have CR-BSI rates below the NNIS rate, our
data indicate that inserting chlorhexidine/sil-
ver sulfadiazine-impregnated catheters in all
patients does not result in a significant decrease
in infections (the study was not powered to
demonstrate a smaller effect). Additional stud-
ies are needed in different ICUs and with dif-
ferent catheters to determine the generalizabil-
ity of these findings.
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